Company profile
Spybiotech Limited is a UK company with status active founded in 2017 based in South East England.
Updated 07 Jul 2026 09:49
Reference milestones and recent Companies House filing stream events.
Next confirmation statement due date
Next accounts due date
Last confirmation statement made up date
Last accounts made up date
SH01 | Transaction MzQ0NDI4MDA3MWFkaXF6a2N4
Published 20 Nov 2024 12:54
Company registered at Companies House
SpyBiotech was founded in March 2017 and employs researchers involved in vaccine development as well as a business development professional. The company is applying technology based on spontaneous isopeptide bond formation towards accelerating vaccine development for human disease. The principal technology is the SpyTag/SpyCatcher peptide/protein interaction but the company is also applying the orthogonal SnoopTag/SnoopCatcher and SnoopLigase systems. Advancement of protein assembly tools during the early stages of this grant has made a contribution to our understanding of evolution of spontaneous isopeptide bond formation.
SpyBiotech uses a biotechnology called superglue technology to develop and produce vaccines.
Vaccine development company
There are 6 full time equivalent posts employed at the company. The company is developing new vaccines and is currently doing pre-clinical testing and seeking to move towards clinical trials.
New labs, local employement, novel vaccine candidates in clinical development phase.
1 May 2023 to 30 Apr 2027
Malaria killed about 640 thousand people in 2020, largely young children in Africa. Rapid recent progress has led to two anti-sporozoite vaccine developers planning WHO prequalification applications in 2022. These include the new high efficacy R21/Matrix-M vaccine, to be supplied at the required large scale, and led by partners in this consortium. In para...
